The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
The Public Health Center of the Ministry of Ukraine (PHC) sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve equitable access to the lifesaving TB drug bedaquiline in ...
Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Ukraine sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...
Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Moldova sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...
Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Azerbaijan sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...
Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...
MSF again called on Gavi to broaden catch-up vaccine coverage for children by waiving co-financing requirements of countries with fragile health systems